Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Ceribell is a hot idea fueled by recent FDA 510(k) approvals for neurological devices, strong 31% YoY revenue growth, expanding market penetration, positive technical momentum with a 27% price rise, and favorable healthcare sector dynamics supporting near-term appreciation potential.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Trend Breakdown ⢠Mid-$16 Support ⢠Overhead Supply Support Level: $16.30-$16.90 Resistance Level: $17.75-$18.25 Over the last month, CBLL has shifted into a clear downtrend from $19.73 to $16.91, with mid-$16s acting as near-term support and the upper-$17s to lower-$18s needing to be reclaimed to improve the trend.
Sentiment & News
Key News Insights: ⢠Earnings date ⢠Conference call ⢠No updates Ceribell scheduled its Q2 2026 earnings release and conference call for Aug. 10, making that update the key near-term catalyst for CBLL.
AI Summary
CBLL is now a âprove-itâ execution story rather than a pure growth narrative, and the next earnings print must confirm durable revenue growth, stable/improving margins, and tight cash burn or the stock's weak technicals and limited upside will likely keep pressure on the shares.
Description
CeriBell, Inc. develops point-of-care EEG technology that uses AI to support detection and management of neurological conditions in acute care settings. Its Ceribell System pairs a bedside EEG platform with disposable headbands and portable recorders to enable rapid monitoring outside traditional neurodiagnostic labs. The company was incorporated in 2014, changed its name from Brain Stethoscope, Inc. in 2015, and is based in Sunnyvale, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 12 | Dec 19 | CBLL | CeriBell, Inc. | Ceribell is a hot idea fueled by recent FDA 510(k) approvals for neurological devices, strong 31% YoY revenue growth, expanding market penetration, positive technical momentum with a 27% price rise, and favorable healthcare sector dynamics supporting near-term appreciation potential. | Closed | +1.2% |